Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haleon PLC Sponsored ADR (HLN – Research Report), Insmed ...

RBC Capital raised the firm’s price target on Haleon (HLN) to 350 GBp from 330 GBp and keeps a Sector Perform rating on the shares.

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with ...

The media giant would separate from the Paris-based conglomerate and is expected to float in London on 16 December, according ...

French media giant Canal+ has set a date for its planned float on the London Stock Exchange today in what could be the ...

Pfizer (NYSE: PFE) is in that group, in my opinion. The big drugmaker's forward dividend yield currently stands at just under ...

Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ETCompany ParticipantsRakesh Patel - Director of Investor ...

Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...